Fluorouracil

About

Therapy type: Chemotherapy

Therapy strategy: Thymidylate synthase inhibition

Mappings

NCI Thesaurus: Fluorouracil (coding:ncit:C505)

RxNorm: fluorouracil (coding:rxcui:4492, coding:omop:4300009)

SNOMED: Fluorouracil (coding:sctid:387172005, coding:omop:955632)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations Biomarkers Cancer types Therapies
FDA (1) HC (1) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Irinotecan
FDA (1) Wild type HRAS, Wild type KRAS Colorectal Adenocarcinoma Fluorouracil, Oxaliplatin, Panitumumab
FDA (1) HC (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab
FDA (1) HC (1) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab
FDA (4) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
FDA (1) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Fluorouracil, Oxaliplatin, Zolbetuximab
FDA (1) HC (1) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin
HC (1) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Nivolumab
HC (1) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Fluorouracil, Nivolumab, Oxaliplatin
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Tislelizumab
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Fluorouracil, Oxaliplatin, Tislelizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Tislelizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Fluorouracil, Oxaliplatin, Tislelizumab
FDA (1) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab
FDA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab
FDA (1) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Irinotecan